Here are the 10-K annual reports from ALX Oncology Holdings Inc. (ALXO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALXO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALXO filings page.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on cancer immunotherapies targeting the CD47 pathway and EGFR. It highlights evorpacept, a CD47 blocker with an inactive Fc domain designed to avoid blood toxicities seen in earlier CD47 drugs, and ALX2004, a novel EGFR-targeted antibody-drug conjugate.
Evorpacept has been studied in gastric, breast, lymphoma and multiple myeloma settings, often combined with antibodies such as trastuzumab, rituximab and zanidatamab. In gastric/GEJ cancer, adding evorpacept to standard HER2-directed therapy improved objective response rates and response duration, especially in tumors with high CD47 expression.
ALX2004, built with an in-house topoisomerase I payload and a matuzumab-derived antibody, showed strong preclinical tumor killing and bystander effect with encouraging non-human primate safety, and is now in a Phase 1 trial in EGFR-expressing solid tumors. As of June 30, 2025, non-affiliate common equity market value was $18.0 million, and 131,608,278 common shares were outstanding as of March 2, 2026.